ClinicalTrials.gg
CompletedNCT03419572CASSIOPEUpdated Aug 15, 2022

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

An observational study in Renal Cell Carcinoma, sponsored by Ipsen. Completed at 91 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-15.

Sponsored by Ipsen · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
689
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Carcinoma, Renal Cell by Ipsen — none open to participants now, 2 under way, none of them phase 3. Carcinoma, Renal Cell · Ipsen.

Enrollment
2nd of 13
689 · median 252
Started
2018
with 3 others
Observational
13 of 16
none open now
Registered
2nd of 16
by date

Among the 16 studies in Carcinoma, Renal Cell by Ipsen, this one is the 2nd largest by enrollment of the 13 observational ones that give a count, is one of 4 that started in 2018, is one of 13 observational ones, and was the 2nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

None of the 16 studies in Carcinoma, Renal Cell by Ipsen is open now. The open studies under Carcinoma, Renal Cell, anywhere →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Carcinoma, Renal Cell by Ipsen as a file.
02

Study summary

The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.

Read the detailed description

The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx™ Summary of Product Characteristics (SmPC).

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with advanced RCC following prior VEGF-targeted therapy in real life settings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old
  • Has a diagnosis of advanced RCC
  • Has received at least one prior VEGF-targeted therapy
  • For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion
  • No previous exposure to cabozantinib prior to inclusion
  • Not concurrently involved in an interventional study
  • Consents to participate in this noninterventional study

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for this study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
689 participants (actual)
Patient registry
No

Groups and cohorts

  • Second line therapy

    Data collection

    Other: Data collection

  • Third and later line therapy

    Data collection

    Other: Data collection

Interventions

  • OtherData collection

    Only available evaluations as decided by the investigator based on local clinical practice will be collected.

This study also gives Cabozantinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with dose modifications due to AEs

    Time frame: 12 months

Secondary outcomes

  1. Reason for cabozantinib dose modification (any modification, reduction, temporary interruption or discontinuation)

    Percentage of subjects with the following reasons - Disease progression, Adverse event, Subject non-compliance, Treatment resumed or re escalated, Subject decision, Clinical / investigator decision, Other

    Time frame: 12 months

  2. Description of number of cabozantinib dose modifications (any modification, reduction, temporary interruption, increase or discontinuation)

    Time frame: 12 months

  3. Median time to first cabozantinib dose modification (any modification, reduction, temporary interruption, increase or discontinuation) due to AEs and for any reason

    Time frame: 12 months

  4. Description of cabozantinib starting dose (combination of dose per intake and frequency)

    Time frame: 12 months

  5. Description of daily dose of cabozantinib received

    Time frame: 12 months

  6. Description of cabozantinib dose intensity (average daily dose compared to starting dose)

    Time frame: 12 months

  7. Duration of cabozantinib treatment (expressed as mean and median time to end of treatment)

    Time frame: 12 months

  8. Proportion of subjects with concomitant radiotherapies

    Time frame: 12 months

  9. Description of systemic therapy (drug name) planned following cabozantinib discontinuation

    Percentage of subjects treated with the following drugs: Sunitinib, Pazopanib, Axitinib, Sorafenib, Bevacizumab, Cytokines, Everolimus, Lenvatinib, Nivolumab, Tivozanib, Experimental trial drug, Other, Unknown)

    Time frame: 12 months

  10. Overall best response

    Per investigator assessment

    Time frame: 12 months

  11. Median Progression Free Survival (PFS) time

    Defined as the time between the start date of cabozantinib and the date of progression or death. Clinical and radiographic (assessed by the investigator based on RECIST 1.1)

    Time frame: 12 months

  12. Overall Survival (OS) rate at the end of the study

    Time frame: 12 months

  13. Health care resource utilisation: number of visits to health care professionals (hospitalisation, surgical procedure, emergency room, physician, homecare by nurse) associated with the management of treatment-related AEs

    Time frame: 12 months

  14. Health care resource utilisation: Description of concomitant medications (by drug class and preferred name) associated with the management of treatment-related AEs

    Time frame: 12 months

  15. Health care resource utilisation: Description of number of unplanned laboratory tests associated with the management of treatment-related AEs

    Time frame: 12 months

Other outcomes

  1. Incidence of all treatment-emergent non-serious and serious AEs

    Time frame: 12 months

07

Study locations

91 sites
  • Kepler University Hospital - Urology
    Linz, 4020, Austria
  • Universitatsklinikum fur Urologie und Andrologie
    Salzburg, 5020, Austria
  • Imelda Ziekenhuis
    Bonheiden, 2820, Belgium
  • Az Klina
    Brasschaat, 2930, Belgium
  • UZA
    Edegem, 2650, Belgium
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
  • Az Damiaan
    Oostende, 8400, Belgium
  • Krajská Nemocnice Liberec, A.S., Komplexní Onkologické Centrum
    Liberec, 460 63, Czechia
  • Thomayerova Nemocnice, Onkologická Klinika 1. LF UK A TN
    Praha 4, 140 59, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady (FNKV) - Radioterapeuticka a Onkologicka klinika
    Praha, 100 34, Czechia
  • Fakultni Nemocnice na Bulovce, Institut of Radiation Oncology
    Praha, 18081, Czechia
  • CHU Angers
    Angers, 49933, France
  • CH Cote Basque
    Bayonne, 64100, France
  • Centre Hospitalier Universitaire
    Besançon, 25030, France
  • Hopital Saint Andre - CHU de Bordeaux
    Bordeaux, 33075, France
  • Centre Catalan d'Urologie
    Cabestany, 66330, France
  • Centre Maurice Tubiana
    Caen, 14000, France
  • CHU Henri Mondor
    Créteil, 94010, France
  • Grenoble University Hospital
    Grenoble, 38043, France
  • Polyclinique Chénieux
    Limoges, 87039, France
  • L'institut Mutualiste Montsouris
    Paris, 75014, France
  • Hospital De Cornouaille
    Quimper, 29107, France
  • Centre de Lutte Contre le Cancer (CLCC) - Institut Jean Godinot
    Reims, 51726, France
  • Institut de Cancérologie Lucien Neuwirth (ICLN)
    Saint-Priest-en-Jarez, 42270, France
  • Strasbourg Oncologie Liberale
    Strasbourg, 67000, France
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67098, France
  • CHU Tours - Hopital Bretonneau
    Tours, 37044, France
  • Vivantes Klinikum Neukolln
    Berlin, 12351, Germany
  • MVZ- Polyclinic Eisenach
    Eisenach, 99817, Germany
  • Universitaetsklinikum Frankfurt - Department of Urology
    Frankfurt, 60590, Germany
  • University Medical Center Halle (Saale)
    Halle, 06120, Germany
  • University Medical Center Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Asklepios Clinic Altona Hamburg
    Hamburg, 22763, Germany
  • University Medical Center LMU Munich - Campus Grosshadern, Urologische Klinik und Poliklinik Marchionnish R. 15
    München, 81377, Germany
  • Universitätsklinikum Münster
    Münster, D-48149, Germany
  • MVP MP Saaletal Saalfeld/Saale
    Saalfeld, 73718, Germany
  • Dept of Urology, Eberhard-Karls-University Tuebingen
    Tuebingen, 72076, Germany
  • University Medical Center Ulm
    Ulm, 89081, Germany
  • Evaggelismos Hospital
    Athens, 10676, Greece
  • Saint Savvas Hospital
    Athens, 11522, Greece
  • Alexandra Hospital
    Athens, 11528, Greece
  • G.O.H.K "Oi Agioi Anargiroi"
    Athens, 14564, Greece
  • Dep. Medical Oncology, University Hospital of Ioannina
    Ioánnina, 45500, Greece
  • Papageorgiou Hospital
    Thessaloníki, 56403, Greece
  • Interbalkan Medical Center
    Thessaloníki, 57001, Greece
  • Azienda Ospedaliera S.Orsola Malpighi di Bologna
    Bologna, 40138, Italy
  • Fondazione IRCCS Istituto Nazionale Dei Tumori
    Milano, 20133, Italy
  • Azienda Ospedaliero Universitaria di Modena
    Modena, 41124, Italy
  • Aorn Cardarelli
    Napoli, 80131, Italy
  • National Cancer Institute "Fondazione G. Pascale" IRCCS
    Napoli, 80131, Italy
  • Umberto Basso
    Padova, 35128, Italy
  • Azienda Ospedaliero-Universitaria di Parma
    Parma, 43126, Italy
  • Fondazione Salvatore Maugeri - I.R.C.C.S
    Pavia, 27100, Italy
  • IRCCS Azienda Usl Di Reggio Emilia
    Reggio Emilia, 42123, Italy
  • Gemelli Hospital
    Roma, 00168, Italy
  • UOC Oncologia Azienda Ospedaliera Sant-Andrea
    Rome, 00189, Italy
  • Presidio Ospedaliero Santa Chiara
    Trento, 38122, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, 37134, Italy
  • San Bortolo General Hospital
    Vicenza, 36100, Italy
  • Amphia Ziekenhuis
    Breda, 4819 EV, Netherlands
  • Deventer Hospital
    Deventer, 7416SE, Netherlands
  • Haaglanden Medical Centre
    Leidschendam, 2262 BA, Netherlands
  • Franciscus Gasthuis Hospital
    Rotterdam, 3118 JH, Netherlands
  • Onkology Center
    Bydgoszcz, 85796, Poland
  • Szpital Kliniczny Przemienienia Panskiego w Poznaniu
    Poznań, 61848, Poland
  • Magodent SP Z O.O.
    Warsaw, 01748, Poland
  • Wojskowy Instytut Medyczny, Klinika Onkologii
    Warsaw, 04141, Poland
  • Dolnoslaskie Centrum Onkologii
    Wrocław, 53413, Poland
  • Hospital Vall de Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital De La Santa Creu I Sant Pau
    Barcelona, 8025, Spain
  • Hospital Dr. Josep Trueta
    Girona, 17007, Spain
  • Hospital Universitario de León
    León, 24080, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
  • Hospital Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Morales Meseguer
    Murcia, 28034, Spain
  • Hospital Virgen de la Victoria
    Málaga, 29017, Spain
  • Hospital Universitario Central de Asturias (Huca)
    Oviedo, 33011, Spain
  • Hospital Universitario Son Espases
    Palma De Mallorca, 07120, Spain
  • Complejo Hospitalario De Navarra
    Pamplona, 31008, Spain
  • Hospital Universitari Parc Tauli
    Sabadell, 08208, Spain
  • Complejo Hospitalario Universitario de Compostela
    Santiago De Compostela, 15706, Spain
  • Hospital Álvaro Cunqueiro de Vigo
    Vigo, 36312, Spain
  • Hospital Clinico Lozano Blesa de Zaragoza
    Zaragoza, 50009, Spain
  • East Kent Hospitals University NHS Foundation Trust
    Canterbury, CT1 3NG, United Kingdom
  • Royal Derby Hospital
    Derby, DE22 3NE, United Kingdom
  • Freeman Hospital-Northern Centre For Cancer Care
    Newcastle, NE7 7DN, United Kingdom
  • Mount Vernon Cancer Centre - East and North Hertfordshire NHS Trust
    Northwood, HA62RN, United Kingdom
  • Rosemere Cancer Centre, Royal Preston Hospital
    Preston, PR2 9HT, United Kingdom
  • Frimley Health NHS Foundation Trust - Wezham Park and Heatherwood Hospitals
    Slough, SL2 4HL, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in May 2022, 48 months.

Of 42 industry-sponsored observational studies under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 91. This study's 48 months is close to that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2017
First posted
Feb 5, 2018
StartActual
Apr 24, 2018
Primary completionActual
May 19, 2022
CompletionActual
May 19, 2022
Last update
Aug 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03419572
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Apr 24, 2018
Primary completion
May 19, 2022
Completion
May 19, 2022
Last update
Aug 15, 2022

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion